Results from last year’s survey (below) were quite strong averaging a 21% YTD gain (outperforming by 660 bps) with 55% of stocks outperforming. Five stocks more than doubled led by Verona Pharma’s 130% gain as the stock was acquired. Other doublers included APP, CRDO, FN and CECO. Our survey for ’24 Best Stocks also did quite well with nearly two-thirds outperforming and around 1000 bps average outperformance.